- Exchange: NASDAQ GS
- Sector: Consumer, Non-cyclical
- Industry: Biotechnology
- Sub-Industry: Medical-Biomedical/Gene
Affymax Inc
+ Add to WatchlistAFFY:US
1.3900 USD 0.0100 0.71%
Share
As of 20:10:00 ET on 05/24/2013.
More on AFFY
News for Affymax Inc (AFFY)
-
COMPANY NEWS
-
PRESS RELEASES
-
INDUSTRY NEWS
- Largest Nasdaq Short Interest Percent Increases as of March 15
- Affymax Falls After Firing 75% of Workers
- Largest Nasdaq Short Interest Percent Increases as of Feb. 28
- Largest Nasdaq Short Interest Changes as of Feb. 28
- Affymax Rises the Most Since 2006: San Francisco Mover
- Affymax Plunges After Recall of Omontys due to Reactions
- Affymax Plunges After Recall of Omontys due to Reactions
- U.S. Stock Options With Biggest Changes in Implied Volatility
- U.S. Stock Options With Biggest Changes in Implied Volatility
- Orbimed Advisors LLC Holdings in 3rd Quarter: 13F Alert
- Implied Stock-Price Moves for U.S. Companies Reporting Results
- Affymax Rises on Deal With Fresenius for Kidney Therapy
- Apollo Global, Arena, Jaguar, Savient: U.S. Equity Movers
- U.S. Stock Options With Biggest Changes in Implied Volatility
- Apollo, McMoRan, PulteGroup, Wabash: U.S. Equity Movers
- Relypsa Announces Appointment of John Orwin as Chief Executive Officer Published May 15, 2013
- Russell J. Howard to Join Prima BioMed's Board of Directors Published May 08, 2013
- Glancy Binkow & Goldberg Encourages Investors to Inquire About a Lead Plaintiff Position in the Class Action Lawsuit Against Published Apr 28, 2013
- SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Affymax, Inc. of Class Action Published Apr 26, 2013
- AFFYMAX 96 HOUR SHAREHOLDER ALERT: Approximately 96 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Published Apr 26, 2013
- Siga Liable Over PharmAthene Contract; Damages Set Aside
- Alex Denner Joins Vivus Activist Slate in Post-Icahn Move
- MS Patients Choose Death Risk With Potent Drug Treatment
- Elan Board Unanimously Rejects $6.4 Billion Takeover Offer
- Novartis Ramps Up Alzheimer’s Drug Pursuit as Rivals Fail
- Hedge Funds Trail S&P 500 by 10 Percentage Points, Goldman Says
- Addex Rises on Positive Rodent Experiment Results: Zurich Mover
- Novartis Sees MorphoSys Muscle-Atrophy Drug as Exciting
- Teva Bets on Reformulating Old Drugs as Investors Say ‘Show Me’
- Royalty Pharma Raises Elan Bid to $12.50 a Share in Cash
- U.K. to Pilot Illumina Genetic Test for Breast, Ovarian Cancer
- Largest Weekly Option Sentiment Changes for S&P 500 Companies
- SAC Digs In as Deadline Nears for U.S. Insider Cases
- Japan Biotech Firms Jump as Abenomics Cash Spurs Speculation
- Puma Biotech Gains After Rival Drug Data Show No Threat
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Advertisements
Advertisement
Rate this Page